Eli Lilly and Company (LLY): Price and Financial Metrics


Eli Lilly and Company (LLY)

Today's Latest Price: $141.31 USD

2.28 (-1.59%)

Updated Oct 21 6:40pm

Add LLY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LLY Stock Summary

  • LLY has a market capitalization of $136,583,969,122 -- more than approximately 98.65% of US stocks.
  • LLY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 95.89% of US stocks.
  • In terms of volatility of its share price, LLY is more volatile than only 1.56% of stocks we're observing.
  • Stocks that are quantitatively similar to LLY, based on their financial statements, market capitalization, and price volatility, are AMGN, TXN, AZN, BMY, and SNY.
  • Visit LLY's SEC page to see the company's official filings. To visit the company's web site, go to www.lilly.com.

LLY Stock Price Chart Interactive Chart >

Price chart for LLY

LLY Price/Volume Stats

Current price $141.31 52-week high $170.75
Prev. close $143.59 52-week low $101.36
Day low $141.21 Volume 1,983,600
Day high $143.33 Avg. volume 3,871,168
50-day MA $149.17 Dividend yield 2.09%
200-day MA $148.89 Market Cap 135.16B

Eli Lilly and Company (LLY) Company Bio


Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company was founded in 1876 and is based in Indianapolis, Indiana.


LLY Latest News Stream


Event/Time News Detail
Loading, please wait...

LLY Latest Social Stream


Loading social stream, please wait...

View Full LLY Social Stream

Latest LLY News From Around the Web

Below are the latest news stories about ELI LILLY & Co that investors may wish to consider to help them evaluate LLY as an investment opportunity.

Fibromyalgia Drugs Market Capacity, Production, Revenue, Price and Gross Margin, Industry Analysis & Forecast by 2026| Pfizer, Eli Lilly, Actavis

Fibromyalgia Drugs Market is expected to grow significantly over next few years and generate considerable market for Fibromyalgia Drugs. Market Report Expert has recently published a research report titled, “ Fibromyalgia Drugs Market Outlook and Statistics, 2020-2026". The report has been

OpenPR | October 2, 2020

Erectile Dysfunction Market Projection By Key Players, Status, Growth, Revenue, SWOT Analysis Forecast 2026| Eli Lilly, Pfizer, Bayer

Erectile Dysfunction Market is expected to grow significantly over next few years and generate considerable market for Erectile Dysfunction. Market Report Expert has recently published a research report titled, “ Erectile Dysfunction Market Outlook and Statistics, 2020-2026". The report has been

OpenPR | October 2, 2020

Global $6 Billion Diabetes Reusable Insulin Delivery Pen Market to 2026 with Sanofi, Ypsomed, Biocon, Novo Nordisk, Eli Lilly and Co, Owen Mumford & Berlin-Chemie Dominating

DUBLIN , Oct. 2, 2020 /PRNewswire/ -- The "Worldwide Diabetes Reusable Insulin Delivery Pen Market: Demand, Insights, Trends, Analysis, Opportunities, Growth Potential and Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Worldwide Diabetes Reusable Insulin Delivery Pen Market size is expected to touch US$ 6 billion by 2026. The report offers the most up-to-date industry data on the actual market situation and future outlook for the worldwide diabetes reusable insulin delivery pen market. The report provides historical market data for 2013 - 2019, and forecasts from 2020 until 2026. The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, reusable insulin pen volume, revenues for reusable...

Benzinga | October 2, 2020

Will President Trump Get Antibody Treatments for Covid-19?

Regeneron and Eli Lilly wouldn’t say whether Mr. Trump would receive their experimental antibody drugs. Regeneron’s C.E.O. has known the president for years.

New York Times | October 2, 2020

Care Access Research Partners on Revolutionary Mobile Clinical Trial for COVID-19 Treatment

BOSTON--(BUSINESS WIRE)--Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced that it is collaborating with global healthcare leader Eli Lilly and Company. Care Access Research is helping Lilly manage the first-of-its-kind system of decentralized, mobile clinical COVID-19 trials as part of the partnership. The BLAZE-2 phase III trial of Lilly's monoclonal antibody (mAb) LY-CoV555, has been initiated nationwide at nursing home

Business Wire | October 1, 2020

Read More 'LLY' Stories Here

LLY Price Returns

1-mo -5.71%
3-mo -10.99%
6-mo -12.44%
1-year 34.29%
3-year 73.52%
5-year 103.55%
YTD 9.11%
2019 16.14%
2018 40.45%
2017 17.83%
2016 -10.37%
2015 25.39%

LLY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full LLY Dividend History

Continue Researching LLY

Want to see what other sources are saying about ELI LILLY & Co's financials and stock price? Try the links below:

ELI LILLY & Co (LLY) Stock Price | Nasdaq
ELI LILLY & Co (LLY) Stock Quote, History and News - Yahoo Finance
ELI LILLY & Co (LLY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7405 seconds.